ALPEGA-GROUP
13.2.2020 17:07:04 CET | Business Wire | Press release
Teleroute, Europe’s leading freight exchange, has announced the launch of Payment Guarantee for carriers. This unique, new service ensures carriers are protected in case of non-payment and is part of Teleroute’s vision to build a truly collaborative network for the transportation industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005649/en/
Teleroute has partnered with Coface, a worldwide leader in credit insurance, to offer a solution that allows carriers to ensure payment for any transport executed using its freight exchange.
Speaking on the launch of Payment Guarantee, Alpega’s Chief Operating Officer, Fabrice Douteaud, said: “Teleroute is Europe’s largest freight and vehicle exchange for domestic and international routes and offers countless opportunities for carriers. However, we know it can be stressful to work with a freight forwarder you know little about, which is why we developed Payment Guarantee. This new service is unique to the market and means carriers can take advantage of the lucrative offers out there, without having to worry about being paid. It’s a great way to open up the market and help businesses make the most of the opportunities out there.”
Carriers can register for Payment Guarantee online, on a case-by-case basis, and receive instant feedback regarding cost and coverage. The ability to guarantee payment for any given transport allows carriers to price their services more competitively and effectively cut costs for shippers and freight forwarders.
Wtransnet, the leading freight exchange in Iberia, has been offering the Payment Guarantee service for more than 15 years and it is one of the solution’s most popular features. Wtransnet became part of the Alpega Group in 2018 and, alongside similar initiatives with Bursa and 123Cargo, the leading freight exchange in Romania, this project illustrates the drive to adapt best practice from across the industry.
The launch of Payment Guarantee sees Teleroute consolidate its position as Europe’s leading freight exchange and highlights its goal of building a truly collaborative transportation network.
In addition to solving spot needs, Teleroute provides more than 70.000 transport companies with significant added value in their day-to-day activities, through its smart and easy to use platform that publishes supply and load demands in real-time.
About Alpega
The Alpega Group is a leading global logistics software company offering end-to-end solutions that cover all transportation needs, including Transport Management Systems (TMS) and Freight Exchanges. The Transport Management Systems (TMS) software solutions – inet and Transwide– connect companies to a broad network of logistics providers and digitize their complex supply chain management. These systems provide live visibility of incoming and outgoing logistics and seamlessly link truck drivers and logistics providers with shippers. The freight exchanges – Teleroute, Wtransnet, Bursa and 123cargo – serve as marketplaces for matching spot shipments and capacities. TenderEasy, for its part, allows shippers to easily send e-tenders to the carrier community. All of the above solutions can be combined to create more added value for customers. Our user community of 80.000 carriers and shippers and 200.000 members are electronically connected every day to successfully manage critical transport processes of 108.000.000 orders every year. Alpega is present in 80 countries worldwide and employs over 500 people with 31 different nationalities.
For more information, visit www.alpegagroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005649/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
